Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
His son Dr Jack Mosley, a GP registrar, who researched GLP-1 drug brands including Ozempic, Wegovy, Mounjaro and Zepbound ...
From the likes of Kathy Bates and Sharon Osbourne to Whoopi Goldberg and Oprah Winfrey, there are a number of stars who have ...
CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...
A RETROSPECTIVE study conducted by Mass General Brigham researchers has found that taking semaglutide before bariatric ...
When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback